UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________________________ FORM 10-K ________________________________________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHA ...

Exhibit 99.1 iRhythm Technologies Announces Fourth Quarter and Full Year 2023 Financial Results SAN FRANCISCO, February 22, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Full Year 2023 Financial Highlights Recent Operational Highlights " ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________ Form 10-Q _______________________________________________________________________ (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 _______ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________ Form 10-Q _______________________________________________________________________ (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 ____________ ...

iRhythm Technologies, Inc. (NASDAQ:IRTC) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Stephanie Zhadkevich - Director of Investor Relations Quentin Blackford - President and Chief Executive Officer Brice Bobzien - Chief Financial Officer Daniel Wilson - Executive Vice President of Corporate Development and Investor Relations Conference Call Participants Margaret Kaczor - William Blair Lily Lozada - JPMorgan Kallum Titchmarsh - Morgan Stanley Marie Thibault - BTIG LLC Samue ...

iRhythm Technologies Second Quarter 2023 Results This presentation and the accompanying oral presentation include forward-looking statements. All statements other than statements of historical facts, including statements regarding our future results of operations and financial position, clinical results, strategy and plans, market size and opportunity, competitive position, industry environment, potential growth opportunities, business model, reimbursement rates and coverage, and our expectations for future ...

iRhythm Technologies, Inc. (NASDAQ:IRTC) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Stephanie Zhadkevich - Director of Investor Relations Quentin Blackford - President & Chief Executive Officer Brice Bobzien - Chief Financial Officer Dan Wilson - EVP of Corporate Development and Investor Relations Conference Call Participants Allen Gong - JPMorgan Marie Thibault - BTIG Nathan Treybeck - Wells Fargo Cecilia Furlong - Morgan Stanley Richard Newitter - Truist Securities Bill P ...

```markdown PART I. FINANCIAL INFORMATION [Item 1. Financial Statements (Unaudited)](index=5&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) This section presents the unaudited condensed consolidated financial statements for Q1 2023, showing **revenue growth of 21% to $111.4 million** and a **net loss improvement to $39.1 million** Condensed Consolidated Statements of Operations (Q1 2023 vs Q1 2022) | Financial Metric | Q1 2023 (in thousands) | Q1 2022 (in thousands) | Change (%) | | :--- | :--- | :--- | :--- | | **Revenue, net** | $111,436 | $92,378 | 20.6% | | **Gross Profit** | $75,681 | $61,759 | 22.5% | | **Loss from Operations** | $(39,504) | $(48,549) | -18.6% | | **Net Loss** | $(39,109) | $(50,609) | -22.7% | | **Net Loss per Share** | $(1.29) | $(1.71) | -24.6% | Condensed Consolidated Balance Sheets | Asset/Liability | March 31, 2023 (in thousands) | December 31, 2022 (in thousands) | | :--- | :--- | :--- | | Cash and cash equivalents | $52,804 | $78,832 | | Total current assets | $253,890 | $288,772 | | **Total Assets** | **$421,701** | **$448,222** | | Total current liabilities | $81,903 | $89,096 | | **Total Liabilities** | **$199,867** | **$208,410** | | **Total Stockholders' Equity** | **$221,834** | **$239,812** | Condensed Consolidated Statements of Cash Flows (Q1 2023 vs Q1 2022) | Cash Flow Activity | Q1 2023 (in thousands) | Q1 2022 (in thousands) | | :--- | :--- | :--- | | Net cash used in operating activities | $(30,753) | $(38,885) | | Net cash provided by (used in) investing activities | $3,820 | $(8,527) | | Net cash provided by financing activities | $905 | $14,636 | [Notes to Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) This section details the company's business, accounting policies, revenue disaggregation, legal proceedings, debt, and stock-based compensation - The company's principal business is the design, development, and commercialization of device-based technology for remote cardiac monitoring services, primarily the **Zio Services**[26](index=26&type=chunk) Revenue by Payor Type (Q1 2023 vs Q1 2022) | Payor Type | Q1 2023 Revenue (in thousands) | % of Revenue | Q1 2022 Revenue (in thousands) | % of Revenue | | :--- | :--- | :--- | :--- | :--- | | Contracted third-party payors | $61,907 | 56% | $51,751 | 56% | | Centers for Medicare and Medicaid | $26,491 | 24% | $20,062 | 22% | | Healthcare institutions | $15,781 | 14% | $15,078 | 16% | | Non-contracted third-party payors | $7,257 | 6% | $5,487 | 6% | | **Total** | **$111,436** | **100%** | **$92,378** | **100%** | - The company is involved in a **securities class action lawsuit** and has received **subpoenas from the U.S. Attorney's Office and the Department of Justice**[86](index=86&type=chunk)[87](index=87&type=chunk) - The company has a development agreement with Verily Life Sciences to develop next-generation atrial fibrillation screening products, with **$11.0 million paid in milestone payments** as of March 31, 2023[88](index=88&type=chunk)[89](index=89&type=chunk) - The company has a loan agreement with SVB (now First-Citizens Bank) for a **$75.0 million term loan facility**, with **$35.0 million drawn** and a **$25.0 million revolving credit line**[94](index=94&type=chunk)[95](index=95&type=chunk)[97](index=97&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=29&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q1 2023 financial performance, noting **21% revenue growth to $111.4 million** and a **narrowed net loss to $39.1 million** Results of Operations Comparison (Q1 2023 vs Q1 2022) | Metric (in thousands) | Q1 2023 | Q1 2022 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | **Revenue** | $111,436 | $92,378 | $19,058 | 21% | | **Gross Profit** | $75,681 | $61,759 | $13,922 | 23% | | **Gross Margin** | 68% | 67% | - | - | | **R&D Expenses** | $14,842 | $10,542 | $4,300 | 41% | | **SG&A Expenses** | $100,343 | $73,158 | $27,185 | 37% | | **Loss from Operations** | $(39,504) | $(48,549) | $9,045 | (19)% | | **Net Loss** | $(39,109) | $(50,609) | $11,500 | (23)% | - Revenue growth was primarily driven by **increased volume of Zio Services** and **improved CMS reimbursement rates**[140](index=140&type=chunk) - The **37% increase in SG&A expenses** was primarily due to a **$13.3 million increase in payroll-related costs** and **$5.7 million in transformation costs**[144](index=144&type=chunk) Reconciliation of Net Loss to Adjusted EBITDA (Non-GAAP) | Metric (in thousands) | Q1 2023 | Q1 2022 | | :--- | :--- | :--- | | Net loss | $(39,109) | $(50,609) | | Stock-based compensation | $18,251 | $13,903 | | Impairment and restructuring charges | $— | $26,608 | | Transformation costs | $5,686 | $258 | | **Adjusted EBITDA** | **$(11,993)** | **$(4,753)** | - As of March 31, 2023, the company had **$52.8 million in cash and cash equivalents** and **$123.5 million in short-term investments**, with management believing current liquidity is sufficient[148](index=148&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=36&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company faces market risks primarily from **interest rate sensitivity** and **foreign currency exchange fluctuations**, neither considered material - The company's primary market risks are **interest rate sensitivity** and **foreign currency exchange rate sensitivity**[165](index=165&type=chunk) - A hypothetical **10% change in interest rates** would have had a **$0.4 million impact on interest income** for Q1 2023[167](index=167&type=chunk)[168](index=168&type=chunk) - Foreign currency exchange risk, primarily from the **British Pound Sterling**, is not considered material[169](index=169&type=chunk) [Controls and Procedures](index=37&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded the company's **disclosure controls and procedures were effective** as of March 31, 2023, with no material changes - The CEO and CFO concluded that the company's **disclosure controls and procedures are effective** at the reasonable assurance level as of March 31, 2023[171](index=171&type=chunk) - There were **no material changes in internal control over financial reporting** during Q1 2023[172](index=172&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=38&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in a **securities class action lawsuit** and **government investigations** by the DOJ, with full cooperation - A **putative securities class action lawsuit** filed in February 2021 is on appeal, which the company believes is without merit[176](index=176&type=chunk) - The company received **grand jury subpoenas** from the U.S. Attorney's Office and a **subpoena from the U.S. Department of Justice** regarding its products and services, with full cooperation[177](index=177&type=chunk) [Risk Factors](index=38&type=section&id=Item%201A.%20Risk%20Factors) This section details numerous risks, including **reimbursement dependency, intense competition, regulatory compliance, supply chain, legal, and cybersecurity threats** - **Reimbursement Risk:** The company's revenue is highly dependent on **Medicare (24% of Q1 2023 revenue)** and commercial payors; policy changes could significantly harm the business[182](index=182&type=chunk)[183](index=183&type=chunk)[186](index=186&type=chunk) - **Regulatory & Compliance Risk:** The company is subject to extensive **FDA regulations**, **healthcare fraud and abuse laws**, and **data privacy laws**; non-compliance could lead to substantial penalties[204](index=204&type=chunk)[206](index=206&type=chunk)[240](index=240&type=chunk) - **Competitive Risk:** The market is highly competitive, with competition from **large medical device companies** and **potential new entrants like Apple** potentially reducing commercial opportunities[194](index=194&type=chunk)[195](index=195&type=chunk) - **Supply Chain Risk:** The company relies on **single-source vendors for critical Zio patch components**; supply disruptions could impair demand fulfillment[213](index=213&type=chunk)[214](index=214&type=chunk)[215](index=215&type=chunk) - **Legal & Investigation Risk:** The company faces a **securities class action lawsuit** and **ongoing government investigations** by the Department of Justice, risking significant liabilities and reputational harm[266](index=266&type=chunk)[268](index=268&type=chunk) - **Cybersecurity Risk:** Handling sensitive patient health information makes the company a target for **cyber-attacks**, risking significant liability and reputational damage[284](index=284&type=chunk)[285](index=285&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=69&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported **no unregistered sales of equity securities** during the period covered by this report - No unregistered sales of equity securities were reported[309](index=309&type=chunk) [Other Information](index=70&type=section&id=Item%205.%20Other%20Information) This section provides the company's **principal executive office address** and details on **material financial information dissemination** - The company's principal executive offices are located at **699 8th Street, Suite 600, San Francisco, CA 94103**[312](index=312&type=chunk) [Exhibits](index=70&type=section&id=Item%206.%20Exhibits) This section lists the **exhibits filed with the Quarterly Report on Form 10-Q**, including CEO/CFO certifications - Exhibits filed include **CEO and CFO certifications** and a **Resignation, Release and Consulting Agreement with former COO Douglas Devine**[313](index=313&type=chunk)[316](index=316&type=chunk) ```

Financial Data and Key Metrics Changes - The company reported revenues of $112.6 million for Q4 2022, reflecting a 38% year-over-year growth and a sequential growth of 8% [69] - Adjusted net loss for Q4 2022 was $17.9 million, or a loss of $0.59 per share, compared to a loss of $19.1 million in Q3 2022 [51] - Full year 2022 revenues reached $410.9 million, representing a 27% growth compared to 2021 [77] - Gross margin for Q4 was 69.9%, with a full year gross margin of 68.5% [50][77] - Adjusted EBITDA for Q4 was positive at $1.1 million, showing significant improvement year-over-year [79] Business Line Data and Key Metrics Changes - The Zio XT service saw strong demand, with new account openings reaching record levels [69] - Home enrollment accounted for about 20% of volume in Q4 2022 [77] - The Zio AT service continued to grow, although at a slower pace compared to the first nine months of 2022 [69] Market Data and Key Metrics Changes - The company anticipates full year revenue growth of approximately 16% to 18% for 2023, amounting to $475 million to $485 million [53] - Approximately 75% of Medicare and commercial patients eligible for coverage now have a $50 co-pay or less [43] Company Strategy and Development Direction - The company is focusing on expanding into primary care, targeting over 14 million patients with cardiac-related issues annually [42] - A nationwide agreement with One Medical has been established to enhance technology-powered solutions [36] - The company plans to launch the next-generation Zio Monitor in the back half of 2023, which is expected to improve patient experience [74] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating operational challenges and expects to see improvements in return device rates and AT business performance [58] - The company is optimistic about the early signs of improvement in healthcare staffing challenges experienced in 2022 [73] - Management highlighted the importance of EHR integration for creating stickiness with accounts and driving growth [30] Other Important Information - The company has cleared material weaknesses in its internal control environment, enhancing operational efficiency [52][80] - The anticipated launch of the Zio Watch is expected to provide complementary monitoring solutions [75] Q&A Session Summary Question: Update on 16% to 18% guidance range and challenges faced - Management feels confident about business progress and expects to navigate through growth headwinds effectively [58] Question: Insights on the new sensor's limited launch - Early indicators from the limited launch of the new sensor are positive, with expectations for a broader launch later in the year [61] Question: Status of AT volumes and growth expectations - The AT business is expected to grow around 30%, with confidence in returning to previous growth levels as operational issues are resolved [92]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________________________ FORM 10-K ________________________________________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHA ...